Hypothesizing dopaminergic genetic antecedents in schizophrenia and substance seeking behavior

Medical Hypotheses

Volumn 82, Issue 5, 2014, Pages 606-614

  Blum, Kenneth ^{a,e,f,g,h,i,j,k}   Oscar Berman, Marlene ^b   Badgaiyan, Rajendra D ^c   Palomo, Tomas ^d   Gold, Mark S ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY AT BUFFALO   (United States)

^d HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^e PATH Foundation   (United States)

^f Department of Personalized Medicine IGENE LLC   (United States)

^g UNIVERSITY OF VERMONT   (United States)

^h Dominion Diagnostics   (United States)

ⁱ Malibu Beach Recovery Center   (United States)

^j RD Solutions LLC Research Center   (United States)

^k Department of Nutrigenomics   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID; ALCOHOL; DOPAMINE; DOPAMINE 2 RECEPTOR; ENKEPHALIN; GAMMA ENDORPHIN; SEROTONIN;

ALLELE; ANTISOCIAL PERSONALITY DISORDER; ANXIETY; ARTICLE; BORDERLINE STATE; COMORBIDITY; CONDUCT DISORDER; CRIMINAL BEHAVIOR; DOPAMINE METABOLISM; DOPAMINE RELEASE; DOPAMINERGIC ACTIVITY; DOPAMINERGIC SYSTEM; DRUG ABUSE; DRUG DEPENDENCE; DRUG SEEKING BEHAVIOR; ENDOPHENOTYPE; GENE FREQUENCY; GENE LINKAGE DISEQUILIBRIUM; GENETIC ANALYSIS; HALLUCINATION; HUMAN; MULTIFACTORIAL INHERITANCE; NEUROIMAGING; NUCLEUS ACCUMBENS; OBSESSIVE COMPULSIVE DISORDER; PANIC; PHENOTYPE; RECEPTOR DENSITY; REINFORCEMENT; REWARD; SCHIZOPHRENIA; SELF MEDICATION; SINGLE NUCLEOTIDE POLYMORPHISM; STRESS; ADDICTION; GENETICS; PATHOPHYSIOLOGY; PHYSIOLOGY; THEORETICAL MODEL;

DOPAMINE; HUMANS; MODELS, THEORETICAL; SCHIZOPHRENIA; SUBSTANCE-RELATED DISORDERS;

EID: 84897112116     PISSN: 03069877     EISSN: 15322777     Source Type: Journal    
DOI: 10.1016/j.mehy.2014.02.019     Document Type: Article

References (224)

1. Kendler K.S., Diehl S.R. The genetics of schizophrenia: a current, genetic-epidemiologic perspective. Schizophr Bull 1993, 19:261-285.
2. Riley B.P. Linkage studies of schizophrenia. Neurotoxicity Res 2004, 6(1):17-34.
3. Fernanadez-Ruiz J, Gomez M, Hennandez M, De Miguel R, Ramos JA. Cannabinoids and gene expression during brain development. in: Palomo T, Beninger R, Kostrezewa, Archer T, editor. Gene-environment interplay in disease states. Neurotoxcity Res. E.P. Graham Publishing Co. 2004 Mountain Home Tenn. USA pp. 389-409. [Chapter 25].
4. Hoenicka J., Ponce G., JiméNez-Arriero M.A., et al. Association in alcoholic patients between Psychopathic Traits and the additive effect of allelic forms of the CNR1 and FAAH endocannabinoid genes, and the 3' Region of the DRD2 Gene. Neurotoxicity Research 2007, 11(1):51-59.
5. Tybura P., Grzywacz A., Samochowiec A., Samochowiec J. Associations between candidate genes with schizophrenia susceptibility and the treatment efficiency. Psychiatr Pol 2011, 45(6):811-823.
6. Snyder S.H. The dopamine hypothesis of schizophrenia: focus on the dopamine receptor. Am J Psychiatry 1976, 133:197-203.
7. Leriche L., Diaz J., Sokoloff P. Dopamine and glutamate dysfunctions in schizophrenia: role of dopamine D3 receptor. Neurotoxicity Res 2004, 6:63-72.
8. Schwartz J.C., Diaz J., Pilon C., Sokoloff P. Possible implication of the dopamine D3 receptor in schizophrenia and in anti-psychotic drug actions. Brain Res Rev 2000, 31:277-278.
9. Lecrubier Y. A partial D3 receptor agonist in schizophrenia. Eur. Neuropsychopharmacol 2003, 13(Suppl. 4):S167-S168.
10. Malhotra A.K. Candidate gene studies of antipsychotic drug efficacy and drug-induced weight gain. Neurotoxcity Res 2004, 6:51-56.
11. 2 receptor gene and clozapine response. Schizophr Res 1999, 1999(36):92-93.
12. 2 receptor gene. Am J Psychiatry 2001, 158:802-804.
13. Mata I., Arranz M.J., Lai T., et al. The seroternergic system influences individual's response to risperidone. Am J Med Genet 2002, 114:728.
14. 2 receptor explain the action of atypical antipsychotics? A new hypothesis. Am J Psychiatry 2001, 158:360-369.
15. Gejman P.V., Ram A., Gelernter J. No structural mutation in the dopamine D2 receptor gene in alcoholism or schizophrenia. Analysis using denaturing gradient gel electrophoresis. JAMA 1994, 271:204-208. 10.1001/jama.1994.03510270050038.
16. Roca M., Martin-Santos R., Saiz J., et al. Diagnostic Interview for Genetic Studies (DIGS): inter-rater and test-retest reliability and validity in a Spanish population. Eur Psychiatry 2007, 22(1):44-48.
17. Mewton L., Teesson M., Slade T., Grove R. The epidemiology of DSM-IV alcohol use disorders amongst young adults in the Australian population. Alcohol Alcohol 2011, 46(2):185-191.
18. Laruelle M., Abi-Dargham A., van Dyck C.H., et al. Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects. Proc Natl Acad Sci USA 1996, 93(17):9235-9240.
19. Blum K., Cull J.G., Braverman E.R., Comings D.E. Reward deficiency syndrome. Am Sci 1996, 84:132-145.
20. van Ree J.M., de Wied D. Neuropeptides and addiction. Neurotxicology 1984, 135-161. Marcel Dekker, Inc, New York, Chapter 7.
21. Volkow N.D., Wang G.J., Begleiter H., et al. High levels of dopamine D2 receptors in unaffected members of alcoholic families: possible protective factors. Arch Gen Psychiatry 2006, 63(9):999-1008.
22. Grandy D.K., Litt M., Allen L., Bunzow J.R., et al. The human dopamine D2 receptor gene is located chromosome 11 at q22-q23 identified a TaqI RFLP. Am J Hum Genet 1989, 45:778-785.
23. Smith M., Wasmuth J., McPherson J.D. Cosegregation of an 11q22.3-9p22 translocation with affective disorder: proximity of the dopamine D2 receptor gene relative to the translocation breakpoint. Am J Hum Genet 1989, 45:A220.
24. 2 receptor gene in alcoholism. JAMA 1990, 263:2055-2060.
25. Blum K., Braverman E.R. Reward deficiency syndrome: a biogenetic model for the diagnosis and treatment of impulsive, addictive and compulsive behaviors. J Psychoactive Drugs 2000, 32:1-112. (Supplement).
26. Ponce G., Jimenez-Arriero M.A., Rubio G., Hoenicka J., Ampuero I., Ramos J.A., et al. The A1 allele of the DRD2 gene (Taq1 A polymorphisms) is associated with antisocial personality in a sample of alcohol-dependent patients. Eur Psychiatry 2003, 18:356-360.
27. Noble E.P., Ozkaragoz T.Z., Ritchie T., Zhang X., Bekin T.R., Sparkes R.S. D2 and D4 dopamine receptor polymorphisms and personality. Am J Med Genet 1998, 81:257-267.
28. Hill S.Y., Zezza N., Wipprecht G., Xu J., Neiswanger K. Linkage studies of D2 and D4 receptor genes and alcoholism. Am J Med Genet 1999, 88(6):676-685.
29. Lowinson J., Ruiz P., Millman R., Langrod J. Substance abuse: a comprehensive textbook 2005, Lippincott William & Wilkens, Philadelphia USA. 4th ed.
30. Comings D.E., Comings B.G., Muhleman D., et al. The dopamine D2 receptor locus as a modifying gene in neuropsychiatric disorders. J Am Med Assoc 1991, 266:1793-1800.
31. Blum K., Braverman E.R., Wood R.C., et al. Increased prevalence of the Taq1 A1 allele of the dopamine receptor gene in obesity with comorbid substance use disorder. Pharmacogenetics 1996, 6:297-305.
32. Blum K., Sheridan P.J., Wood R.C., Braverman E.R., Chen T.J., Comings D.E. The D2 dopamine receptor gene as a determinant of reward deficiency syndrome. J R Soc Med 1996, 89(7):396-400.
33. Ratsma J.E., van der Stelt O., Schoffelmeer A.N.M., Westerveld A., Ginning W.B. P3 event-related potential, dopamine D2 A1 allele, and sensation-seeking in adult children of alcoholics. Alcohol Clin Exp Res 2001, 25:960-967.
34. Romstad A., Dupont E., Krag-Olsen B., Ostergaard K., Guldberg P., Guttler F. Dopa-responsive dystonia and Tourette syndrome in a large Danish family. Arch Neurol 2003, 60(4):618-622.
35. Singer H.S., Szymanski S., Giuliano J., et al. Elevated intrasynaptic dopamine release in Tourette's syndrome measured by PET. Am J Psychiatry 2002, 159(8):1329-1336.
36. Smith K.M., Daly M., Fischer M., Yiannoutsoss C.T., Bauer L., Barkley R., et al. Association of the dopamine beta hydroxylase gene with attention deficit hyperactivity disorder: genetic analysis of the Milwaukee longitudinal study. Am J Med Genet 2003, 119(1):77-85.
37. 2 receptor gene. Mol Psychiatry 1996, 1:325-335.
38. Comings D.E., Wu S., Chiu C., et al. Polygenic inheritance of Tourette syndrome, stuttering, attention deficit hyperactivity, conduct, and oppositional defiant disorder: The additive and subtractive effect of the three dopaminergic genes DRD2, DBH, and DAT1. Am J Med Genet 1996, 67:264-288.
39. Comings D.E., Gade-Andavilu R., Gonzalez N., et al. Multivariate analysis of associations of 42 genes in ADHD ODD and conduct disorder. Clin Genet 2000, 58:31-40.
40. Comings D., Johnson P., Dietz G., Muhleman D. Dopamine D2 receptor gene (DRD2) haplotypes and the defense style questionnaire in substance abuse, Tourette syndrome and controls. Biol Psychiatry 1995, 37:798-805.
41. Blum K., Kozlowski G.P. Ethanol and neuromodulator interactions: a cascade model of reward. Alcohol and behavior 1990, 131-149. VSP Press, Utrecht, Netherlands.
42. Rowe D.C. Genetic and environmental components of antisocial behavior: A study of 265 twin pairs. Criminology 1986, 24:513-532.
43. Cools A.R., Gingras M.A., Nijmegen J. High and low responders to novelty: a new tool in the search after the neurobiology of drug abuse liability. Pharmacol Biochem Behav 1998, 60:151-159.
44. Comings D.E., Gade-Andavolu R., Gonzalez N., et al. The additive effect of neurotransmitter genes in pathological gambling. Clin Genet 2001, 60(2):107-116.
45. Reuter J., Raedler R., Rose M., Hand I., Glasher, Buchel C. Pathologucal gambling is linked to reduced activation of the mesolimbic system. Nature Neurosci 2005, 8:147-148.
46. Eshleman A.J., Henningsen R.A., Neve K.A., Janowsky A. Release of dopamine via the human transporter. Mol Pharmacol 1994, 45:312-316.
47. Carboni E., Silvagni A., Rolando M.T.P., Di Chiara G. Stimulation of in vivo dopamine transmission in the bed nucleus of stria terminalis by reinforcing drugs. J Neurosci 2000, 20:1-5.
48. Gessa G.l., Mutoni F., Coller M., Vargin L., Mercer G. Low doses of ethanol activate dopaminergic neurons in the ventral tegmental area. Brain Res 1985, 348:201-203.
49. Di Chiara G. Drug addiction as dopamine-dependent associative learning disorder. Eur J Pharmacol 1999, 375:13-30.
50. Di Chiara G. Nucleus accumbens shell and core dopamine: differential role in behavior and addiction. Behav Res 2002, 137:75-114.
51. Di Chiara G., Tanda G., Bassare V., et al. Drug addiction as a disorder of associative learning, role of nucleus accumbens shell/extended amygdala dopamine. Ann NY Acad Sci 1999, 877:461-485.
52. Di Chiara G., Impereto A. Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic systems of freely moving rats. Proc Natl Acad Sci USA 1988, 84:1413-1416.
53. Blum K., Noble E.P., Sheridan P.J., Finley O., Montgomery A., Ritchie T., et al. Association of the A1 allele of the D2 dopamine receptor gene with severe alcoholism. Alcohol 1991, 8:409-416.
54. Adler C.M., Elman I., Weisenfield N., Kestler L., Pickar D., Breier A. Effects of acute metabolic stress on striatal dopamine release in healthy volunteers. Neuropsychopharmacolgy 2000, 22(5):545-550.
55. Hallbus M., Magnusson T., Magnusson O. Influence of 5-HT1B/1D receptors on dopamine release in the guinea pig nucleus accumbens: a microdialysis study. Neurosci Lett 1997, 225:57-60.
56. Koepp M.J., Gunn R.N., Lawrence A.D., et al. Evidence for striatal dopamine release during a video game. Nature 1998, 393:266-268.
57. Noble E.P., Noble R.E., Ritchie T., Grandy D.K., Sparkes R.S. D2 Receptor gene and obesity. Int J. Eat Disord 1994, 15:205-217.
58. Comings D.E., Blum K. Reward deficiency syndrome: genetic aspects of behavioral disorders. Prog Brain Res 2000, 126:325-341.
59. Koob G.F. Alcoholism: allostasis and beyond. Alcohol Clin Exp Res 2003, 27(2):232-243.
60. Koob G.F., Le Moal M. Drug addiction, dysregulation of reward, and allostasis. Neuropsychopharmacol 2001, 24:97-129.
61. Dick D.M., Edenberg H.J., Xuei X., et al. Association of GABAG3 with alcohol dependence. Alcohol Clin Exp Res 2004, 28(1):4-9.
62. Goldman D., Dean M., Brown G.L., Bolos A.M., Tokola R., Virkkunen M., et al. D2 dopamine receptor genotype and cerebrospinal fluid homovanillic acid, 5-hydroxyindoleacetic acid and 3-methoxy-4-hydroxyphenylglycol in alcoholisms in Finland and the United States. Acta Psychiatr Scand 1992, 86:351-357.
63. Comings D.E., Dietz G., Johnson J.P.M.J.P. Association of the enkephalinase gene with low amplitude P300 waves. Neuroreport 1999, 1999(10):2283-2285.
64. Gardner E.L. Brain reward mechanisms. Substance abuse: a comprehensive textbook 1997, 51-58. Lippincott Williams & Wilkins. J.H. Lowenson, P. Ruiz, R.B. Millman, J.G. Langrod (Eds.).
65. Connor J.P., Young R.M., Lawford B.R., Ritchie T.L., Noble E.P. D2 dopamine receptor (DRD2) polymorphism is associated with severity of alcohol dependence. Eur Psychiatry 2002, 17:17-23.
66. Rommelspacher H., Raeder C., Kaulen P., Bruning G. Adaptive changes of dopamine-D2 receptors in rat brain following ethanol withdrawal: a quantitative autoradiographic investigation. Alcohol 1992, 9:355-362.
67. Blum K., Noble E.P., Sheridan P.J., Finley O. Association of the A1 allele of the D2 dopamine receptor gene with severe alcoholism. Alcohol 1991, 8(5):409-416.
68. Blum K., Sheridan P.J., Noble E.P. The A1 allele of the dopamine D2 receptor gene as a genetic marker for risk of severe alcoholism. Biological psychiatry vol. 2 1991, vol. 2:14-17. Elsevier Science Publishers B.V., Amsterdam.
69. Blum K., Noble E.P., Sheridan P.J., et al. Genetic predisposition in alcoholism: association of the D2 dopamine receptor TaqI B1 RFLP with severe alcoholics. Alcohol 1993, 10:59-67.
70. O'Hara B.F., Smith S.S., Bird G., et al. Dopamine D2 receptor RFLPs, haplotypes and their association with substance use in black and Caucasian research volunteers. Hum Hered 1993, 43(4):209-218.
71. Comings D.E., Muhlman D., Ahn C., Gysin R., Flanagan S.D. The dopamine D2 receptor gene: a genetic risk factor in substance abuse. Drug Alcohol Depend 1994, 34:175-180.
72. Noble E.P., Blum K., Ritchie T., Montgomery A., Sheridan P. Allelic association of the D2 dopamine receptor gene with receptor-binding characteristics. Arch Gen Psychiatry 1991, 48:648-654.
73. Parsian A., Todd R.D., Devor E.J., O'Malley K.L., Suarez B.K., Reich T., et al. Alcoholism and alleles of the human D2 dopamine receptor locus: Studies of Association and linkage. Arch Gen Psychiatry 1991, 48:655-663.
74. Parsian A., Cloninger C.R., Zhang Z.H. Functional variant in the DRD2 receptor promoter region and subtypes of alcoholism. Am J Med Genet 2000, 96:407-411.
75. Noble E.P., Syndilko K., Fitch R.J., et al. D2 dopamine receptor Taq1 A alleles in medically ill alcoholic and nonalcoholic patients. Alcohol Alcohol 1994, 29:729-744.
76. Lawford B.R., Young R.M., Rowell J.A., et al. A1 allele with alcoholism: medical severity of alcoholism and type of controls. Biol Psychiatry 1997, 41:386-393.
77. Lawford B.R., Young R.M., Rowell J.A., et al. Bromocriptine in the treatment of alcoholics with the D2 dopamine receptor A1 allele. Nat Med 1995, 1(4):337-341.
78. Neiswanger K., Kaplan B.B., Hill S.Y. What can the DRD2/alcoholism story teach us about association studies in psychiatric genetics?. Am J Med Genet 1995, 60(4):272-275.
79. Hietata J., West C., Syvalahti E., Nagren K., Lehikoinen P., Sonninen U. Striatal D2 dopamine receptor binding characteristics in vivo in patients with alcohol dependence. Psychopharmacol 1994, 116:285-290.
80. Hill S.Y. Alternative strategies for uncovering genes contributing to alcoholism risk: unpredictable findings in a genetic wonderland. Alcohol 1998, 16:53-59.
81. Hill S.Y., Neiswanger K. The value of narrow psychiatric phenotypes and "super" normal controls. Handbook of psychiatric genetics 1997, CRC Press, Boca Raton.
82. Hill S.Y., Zezza N., Wipprecht G., Locke J., Neiswanger K. Personality traits and dopamine receptors (D2 & D4): linkage studies in families of alcoholics. Am J Med Genet 1989, 88:634-641.
83. Bau C.H.D., Almeida S., Hutz M.H. The TaqI A1 allele of the dopamine D2 receptor gene and alcoholism in Brazil: association and interaction with stress and harm avoidance on severity prediction. Am J Med Genet 2000, 96:302-306.
84. Laine T.P.J., Ahonen A., Torniainen P., et al. Dopamine transporter increase in human brain after alcohol withdrawal. Mol Psychiatry 1999, 4:189-191.
85. Laine T.P., Ahonen A., Rasanen P., Tiihonen J. Dopamine transporter availability and depressive symptoms during alcohol withdrawal. Psychiatry Res 1999, 90:153-157.
86. Arinami T., Itokawa M., Komiyama T., et al. Association between severity of alcoholism and the A1 allele of the dopamine D2 receptor gene TaqI A RFLP in Japanese. Biol Psychiatry 1993, 33:108-114.
87. Kono Y., Yoneda H., Sakai T., et al. Association between early-onset alcoholism and the dopamine D2 receptor gene. Am J Med Genet 1997, 74:179-182.
88. Goldman D., Brown G.L., Albaugh B., et al. DRD2 dopamine receptor genotype, linkage diseqilibrium and alcoholism. In American Indians and other populations. Alcohol Clin Exp Res 1993, 17:199-204.
89. Goldman D., Dean M., Brown G.L., et al. D2 dopamine receptor genotype and cerebrospinal fluid homovanillic acid, 5-hydroxyindoleacetic acid and 3-methoxy-4-hydroxyphenylglycol in alcoholisms in Finland and the United States. Acta Psychiatr Scand 1992, 86:351-357.
90. Goldman D., Urbanek M., Guenther D., Robin R., Long J.C. Linkage and association of a functional DRD2 variant [Ser311Cys] and DRD2 markers to alcoholism, substance abuse and schizophrenia in Southwestern American Indians. Am J Med Genet 1997, 74:386-394.
91. Xu K., Lichterman D., Kipsky R.H., et al. Association of specific haplotypes of D2 dopamine receptor gene with vulnerability to heroin dependence in distinct populations. Arch Gen Psychiatry 2004, 61:567-606.
92. Bolos A.M., Dean M., Lucas-Derse S., Ramsburg M., Brown G.L., Goldman D. Population and pedigree studies reveal a lock of association between the dopamine D2 receptor gene and alcoholism. JAMA 1990, 264:3156-3160.
93. Gelernter J., O'Malley S., Risch N., et al. No association between an allele at the D2 dopamine receptor gene (DRD2) and alcoholism. JAMA 1991, 266:1801-1907.
94. Gelernter J., Goldman D., Risch N. The A1 allele at the D2 dopamine receptor gene and alcoholism. A reappraisal. JAMA 1993, 269:1673-1677.
95. Cook B.L., Wang Z.W., Crowe R.R., Hauser R., Freimer M. Alcoholism and the D2. Alcohol Clin Exp Res 1992, 16(4):806-809.
96. Turner E., Ewing J., Shilling P., Smith T.L., Irwin M., Schuckit M., et al. Lack of association between an RFLP near the D2 dopamine receptor gene and severe alcoholism. Biol Psychiatry 1992, 3:285-290.
97. Suarez B.K., Parsian A., Hampe C.L., Todd R.D., Reich T., Cloninger C.R. Linkage disequilibria at the D2 dopamine receptor locus (DRD2) in alcoholics and controls. Genomics 1994, 19:12-20.
98. Chen C.H., Chien S.H., Hwu H.G. Lack of association between TaqI A1 allele of dopamine D2 receptor gene and alcohol-use disorders in atayal natives of Taiwan. Am J Med Genet 1996, 67:488-490.
99. Chen W.J., Loh E.W., Hsu Y.P., Cheng A.T. Dopamine D2 receptor gene and alcoholism among four aboriginal groups and han in Taiwan. Am J Med Genet 1997, 74:129-136.
100. Cruz C., Camarena B., Mejia J.M., et al. The dopamine D2 receptor gene TaqI A1 polymorphism and alcoholism in a Mexican population. Arch Med Res 1995, 26:421-426.
101. Gejman P.V., Gelernter R.J., Friedman E., et al. No structural mutation in the dopamine D2 receptor gene in alcoholism or schizophrenia. Analysis using denaturing gradient gel electrophoresis. JAMA 1994, 271(3):204-209.
102. Edenberg H.J., Foroud T., Koller D.L., et al. A family-based analysis of the association of the dopamine D2 receptor (DRD2) with alcoholism. Alcohol Clin Exp Res 1998, 22:505-512.
103. Gebhardt C., Leisch F., Schussler P., et al. Non-association of dopamine D4 and D2 receptor genes with personality in healthy individuals. Psychiatr Genet 2000, 10:131-137.
104. Lu R.B., Ko H.C., Chang F.M., Yin S.J., Pakstis A.J., Kidd K.K. No association between alcoholism and multiple polymorphism at the dopamine D2 receptor gene (DRD2) in three distinct Taiwanese populations. Biol Psychiatry 1996, 39:419-429.
105. Merikangas K.R. The genetic epidemiology of alcoholism. Psychol Med 1990, 20:11-22.
106. Gorwood P. Contribution of genetics to the concept of risk status for alcohol dependence. J Soc Biol 2000, 194(1):43-49.
107. Noble E.P. DRD2 gene and alcoholism. Science 1998, 281(5381):1287-1288.
108. Noble E.P. The D2 dopamine receptor gene: a review of association studies in alcoholism and phenotypes. Alcohol 1998, 16:33-45.
109. Noble E.P. The DRD2 gene in psychiatric and neurological disorder and its phenotypes. Pharmacogenomics 2000, 1(3):309-333.
110. Noble E.P. D2 dopamine receptor gene in psychiatric and neurologic disorders and its phenotypes. Am J Med Genet 2003, 116B:103-125.
111. Bowirrat A., Oscar-Berman M. Relationship between dopaminergic neurotransmission, alcoholism, and reward deficiency syndrome. Am J Med Gen Part B. Neuropsychiatr Genet 2005, 132B(1):29-37.
112. Barr C.L., Kidd K.K. Population frequencies of the A1 allele at the dopamine D2 receptor locus. Biol Psychiatry 1993, 34:204-209.
113. Blum K., Payne J. Alcohol and the addictive brain 1991, The Free Press Simon, Schuster New York NY.
114. Bouchard T.J. Genes, environment and personality. Science 1994, 9:415-421.
115. Cadoret R.J., Troughton E., Bagford J., Woodworth G. Genetic and environmental factors in adoptee antisocial personality. Eur Arch Psychiatry Neurol Sci 1990, 239:231-240.
116. Carey G. Genetic association study in psychiatry: analytical evaluation and a recommendation. Am J Med Genet (Neuropsychiatr Genet) 1994, 54:311-317.
117. Crowe R.R. Candidate genes in psychiatry: an epidemiological perspective. Am J Med Genet (Neuropsychiatr Genet) 1993, 48:74-77.
118. Grandy D.K., Eubanks J.H., Evans G.A., Civelli O., Litt M. Detection and characterization of additional DNA polymorphisms in the dopamine D2 receptor gene. Genomics 1991, 10(3):527-530.
119. Greenberg D.A. Linkage analysis of "necessary" disease loci versus "susceptibility" loci. Am J Hum Genet 1993, 52:135-143.
120. Oakley N.R., Hayes A.G., Sheehan M.J. Effect of typical and atypical neuroleptics on the behavioural consequences of activation by muscimol of mesolimbic and nigrostriatal dopaminergic pathways in the rat. Neuropharmacol (Berl) 1991, 105(2):204-208.
121. Pato C.N., Macciardi F., Pato M.T., Verga M., Kennedy J.L. Review of the putative association of dopamine D2 receptor and alcoholism. Am J Med Genet (Neuropsychiatr Genet) 1993, 48:78-82.
122. Pickens R.W., Svikis D.S., McGue M., Lykken D.T., Heston L.L., Clayton C.J. Heterogeneity in the inheritance of alcoholism. Arch Gen Psychiatry 1991, 43:19-28.
123. Clark W.R., Grunstein Are we hardwired? the role of genes in human behavior 2000, Oxford University Press, New York.
124. Hodge S.E. What association analysis can and cannot tell us about the genetics of complex disease. Am J Med Genet (Neuropsychiatr Genet) 1994, 54:318-323.
125. Plomin R., Owen M.J., McGuffin P. The genetic basis of complex human behaviors. Science 1994, 264:1733-1739.
126. Volkow N.D., Wang G.J., Fowler J.S., et al. Decreases in dopamine receptors but not in dopamine transporters in alcoholics. Alcohol Clin Exp Res 1996, 20:1594-1598.
127. Tiihonen J., Kuikka J., Bergstrom K., Hakola P., Kalni J., Rynanen O.P., et al. Altered striatal dopamine re-uptake site densities in habitually violent and non-violent alcoholics. Nat Med 1995, 1:654-657.
128. Kuikka J.T., Baulieu J.L., Hiltunen J., et al. Pharmacokinetics and dosimetry of iodine-123 labeled PE2I in humans, a radioligand for dopamine transporter imaging. Eur J Nucl Med 1998, 25:531-534.
129. Little K.Y., McLaughlin D.P., Zang L., et al. Brain dopamine transporter messenger RNA and binding sites in cocaine users. Arch Gen Psychiatry 1998, 55:793-799.
130. Little K.Y., Zang L. Striatal dopaminergic abnormalities in human cocaine users. Am J Psychiatry 1999, 156:238-245.
131. Repo E., Kuikka J.T., Bergstrom K.A., Karhu J., Hiltunen J., Tiihonen J. Dopamine transporter and D2-receptor density in late-onset alcoholism. Psychopharmacol 1999, 147:314-318.
132. Kuikka J.T., Repo E., Bergstrom K.A., Tupala E., Tiihonen J. Specific binding and laterality of human extrastriatal dopamine D2/D3 receptors in the late onset type 1 alcoholic patients. Neurosci Lett 2000, 292(1):57-59.
133. Panagis G., Nomikos G.G., Miliaressis E., Chergui K., Kastellakis A., Svensson T.H., et al. Ventral pallidum self-stimulation induces stimulus dependent increase in c-fos expression in reward-related brain regions. Neuroscience 1997, 77(1):175-186.
134. Jonsson E.G., Cichon S., Gustavsson P., et al. Association between a promoter dopamine D2 receptor gene variant and the personality trait detachment. Biol Psychiatry 2003, 53:577-584.
135. Kreek M.J., Koob G.F. Drug dependence. Stress and dysregulation of brain reward pathways. Drug Alcohol Depend 1998, 51(1-2):23-47.
136. Neville M.J., Johnstone E.C., Walton R.T. Identification and characterization of ANKK1: a novel kinase gene closely linked to DRD2 on chromosome band 11q23.1. Human Mutat 2004, 23:540-545.
137. Robbins T.W., Everitt B.J. Neurobiobehavioural mechanisms of reward and motivation. Curr Opin Neurobiol 1996, 6:228-236.
138. Wightman R.M. Robinson DL transient changes in mesolimbic dopamine and their association with "reward". J Neurochem 2002, 82:721-735.
139. Epping-Jordan M.P., Markou A., Koob G.F. The dopamine D-1 receptor antagonist SCH 23390 injected into the dorsolateral bed nucleus of the stria terminalis decreased cocaine reinforcement in the rat. Brain Res 1998, 784:105-115.
140. Cooper M., Frone M., Russell M., Mudar P. Drinking to regulate positive and negative emotions: a motivational model of alcohol use. J Pers Soc Psychol 1995, 69:990-1005.
141. Suhara T., Yasuno F., Sudo Y., Yamamoto M., Inoue M., Okubo Y., et al. Dopamine D2 receptors in the insular cortex and the personality trait of novelty seeking. Neuroimage 2001, 13:891-895.
142. Hodge C.W., Chappelle A.M., Samson H.H. Dopamine receptors in the medial prefrontal cortex influence ethanol and sucrose-reinforced responding. Alcohol Clin Exp Res 1996, 20(9):1631-1638.
143. Hodge C.W., Cox A.A. The discriminative stimulus effects of ethanol are mediated by NMDA and GABA (A) receptors in specific limbic brain regions. Psychopharmacol (Berl) 1998, 139:95-107.
144. Koehnke M.D., Schich S., Lutz U., Willecke M., Koehnke A.M., Kolb W., et al. Severity of alcohol withdrawal symptoms and the T1128C polymorphism of the neuropeptide Y gene. J Neural Transm 2002, 109(11):1423-1429.
145. Kelley A.E., Berridge K.C. The neuroscience of natural rewards: relevance to addictive drugs. J Neurosci 2002, 22:3306-3311.
146. Grant K.A. Emerging neurochemical concepts in the actions of ethanol at ligand-gated ion channels. Behav Pharmacol 1994, 5:383-404.
147. Gordon A.S., Yao L., Jiang Z., Fish burn C.S., Fuchs S., Diamond I. Ethanol acts synergistically with a D2 dopamine agonist to cause translocation of protein kinase C. Mol Pharmacol 2001, 59:153-160.
148. Lobos E.A., Todd R.D. Association analysis in an evolutionary context: cladistic analysis of the DRD2 locus to test for association with alcoholism. Am J Med Genet 1998, 81:411-419.
149. Hutchison K.E., McGeary J., Smolen A., Bryan A., Swift R.M. The DRD4 VNTR polymorphism moderates craving after alcohol consumption. Health Psychol 2002, 21(2):139-146.
150. Myers R.D., Robinson D.E. Mu and D2 receptor antisense oligonucleotides injected in nucleus accumbens suppress high alcohol intake in genetic drinking HEP rats. Alcohol 1999, 18(2-3):225-233.
151. Mash D.C., Staley J.K., Doepel F.M., Young S.N., Ervin F.R., Palmour R.M. Altered dopamine transporter densities in alcohol-preferring vervet monkeys. Neuro Rep 1996, 7:457-462.
152. Comings D.E., Muhleman D., Gysin R. Dopamine D2 receptor (DRD2) gene and susceptibility to posttraumatic stress disorder: a study and replication. Biol Psychiatry 1996, 40:368-372.
153. Kotter R. Stephan KE Useless or helpful? The "limbic system" concept. Rev Neurosci 1997, 8:139-145.
154. Oscar-Berman M. Neuropsychological vulnerabilities in chronic alcoholism. In: Noronha A, Eckardt M, Warren K, editors. Review of NIAAA's neuroscience and behavioral research portfolio. National Institute on Alcohol Abuse and Alcoholism Research Monograph-34. Bethesda, MD: The Institute 2000 pp 149-158.
155. Oscar-Berman M., Hutner N. Alcoholism. The Blackwell dictionary of neuropsychology 1996, 33-38. Blackwell Publishers, Cambridge, MA. J.G. Beaumont, P.M. Kenealy, M.J.C. Rogers (Eds.).
156. Oscar-Berman M., McNamara P., Freedman M. Delayed-response tasks: parallels between experimental ablation studies and finding in patients with frontal lesions. Frontal lobe function and injury 1991, 231-255. Oxford University Press, NY. H.S. Levin, H.M. Eisenberg, A.L. Benton (Eds.).
157. Koob G.F. Neurobiology of addiction: toward the development of new therapies. Ann N Y Acad Sci 2000, 909:170-185.
158. Arinami T., Itokawa M., Aoki J., Shibuya H., Ookubo Y., Iwawaki A., et al. Further association study on dopamine D2 receptor S311C in schizophrenia and affective disorders. Am J Med Genet 1996, 67(2):133-138.
159. Comings D.E., Comings B.G., Muhleman D., et al. The dopamine D2 receptor locus as a modifying gene in neuropsychiatric disorders. JAMA 1991, 266:1793-1800.
160. Golimbet V.E., Aksenova M.G., Nosikov V.V., Orlova V.A., Kaleda V.G. Analysis of the linkage of the Taq 1A and Taq 1B loci of the dopamine D2 receptor gene with schizophrenia in patients and their siblings. Neurosci Behav Physiol 2003, 33(3):223-225.
161. Schindler K.M., Pato M.T., Dourado A., et al. Association and linkage disequilibrium between a functional polymorphism of the dopamine-2 receptor gene and schizophrenia in a genetically homogeneous Portuguese population. Mol Psychiatry 2002, 7(9):1002-1005.
162. Noble E.P., Zhang X., Ritchie T., et al. D2 dopamine receptor and GABA (A) receptor beta3 subunit gene alcoholism. Psychiatr Res 1998, 81:133-147.
163. Parsons L.H., Weiss F., Koob G.F. Serotonin 1b receptor stimulation enhances dopamine-mediated reinforcement. Psychopharmacol 1996, 128:150-160.
164. B receptor agonists and antagonists. Brain Res 1993, 630:28-31.
165. Tupala E., Hall H., Bergstrom K., et al. Dopamine D(2)/D(3)-receptor and transporter densities in nucleus accumbens and amygdala of type 1 and type 2 alcoholics. Mol Psychiatry 2001, 6(3):261-267.
166. Tupala E., Kuikka J.T., Hall H., et al. Measurement of the striatal dopamine transporter density and heterogeneity in type 1 alcoholics using human whole hemisphere autoradiography. Neuroimage 2001, 1:87-94.
167. Pilla M., Perachon S., Sautel F., et al. Selective inhibition of cocaine-seeking behaviour by a partial dopamine D3 receptor agonist. Nature 1999, 400(6742):371-375.
168. Comings D.E., Wu S., Chiu C., et al. Polygenic inhertance of Tourette Syndrome, stuttering, attention-deficit-hyperactivity, conduct and oppositional defiant disorder. The addictive and subtractive effect of the three dopaminergic genes-DRD2, DBH and DAT1. Am J Med Gen (Neuropsychiatr Genet) 1996, 67:264-288.
169. Tupala E., Hall H., Bergstrom K., et al. Dopamine D2 receptors and transporters in type 1 and 2 alcoholics measured with human whole hemisphere autoradiography. Hum Brain Mapp 2003, 20(2):91-102.
170. Walsh S.L., Cunningham K.A. Serotonergic mechanisms involved in the discriminative stimulus, reinforcing and subjective effects of cocaine. Psychopharmacol 1997, 130:41-58.
171. Comings D.E., Blake H., Dietz G., et al. The preenkephalin gene(PENK) and opioid dependence. Neuroreport 1999, 10:1133-1135.
172. Comings D.E., Muhleman D., Wu S., McMurray J.P. Association of the N-alpha-acetyltransferase gene (NAT1) with mild and sever substance abuse. Neuroreport 2000, 11(6):1227-1230.
173. Ary A.W., Lominac K.D., Wroten M.G., et al. Imbalances in prefrontal cortex CC-Homer1 versus CC-Homer2 expression promote cocaine preference. J Neurosci 2013, 33(19):8101-8113.
174. Comings D.E., Gade R., Wu S., Chiu C., et al. Studies of the potential role of the dopamine D1 receptor gene in addictive behaviors. Mol Psychiatry 1997, 2:44-56.
175. Comings D.E., Gade R., Muhlman D., et al. Exon and intron variants in the human tryptophan 2,3 dioxygenase gene: Potential association with Tourette syndrome, substance abuse and other disorders. Pharmacogenetics 1996, 6:307-318.
176. Versteeg D.H., Van Heuven-Nolsen D., De Wied D. Pre-decapitation state of arousal of rats predetermines the effect of des-Tyr1-gamma-endorphin on dopamine release from nucleus accumbens slices in vitro. Life Sci 1984, 34(16):1549-1554.
177. - gamma-endorphin; DT gamma E). Eur J Pharmacol 1978, 49:427-436.
178. van Ree J.M., Witter A. Leysen JE Interaction of des-tyrosine-gamma-endorphin with neuroleptic binding sites in various areas of rat brain. Eur J Pharmacol 1978, 52:411-413.
179. van Ree J.M., Caffe A.M., Wolterink G. Non-opiate Beta-endorphin fragments and dopamine. III. Gamma-type endorphins and various neuroleptics counteract the hyperactivity elicited by injection of apomorphine into the nucleus accumbens. Neuropharmacology 1982, 21:1111-1117.
180. van Ree J.M., De Wied D. Neuroleptic-like profile of gamma type endorphins as related to schizophrenia. Trends Pharmacol Sci 1982, 3:358-361.
181. De Wied D. Psychopathology as a neuropeptide dysfunction. Characteristics and function of opioids 1978, 113-122. Elsevier/North-Holland, Amsterdam.
182. van Ree J.M., Verhoeven W.M.A., De Wied D., Van Praag H.M. The use of the synthetic peptides gamma-type endorphins in mentally ill patients. Ann NY Acad Sci 1982, 398:478-495.
183. 1]-gamma-endorphin (DTgamma E). Arch Gen Psychiatry 1979, 36:294-298.
184. Jackson H.C., Ramsay E., Nutt D.J. Attenuation of the behavioral effects of ethanol in mice by des-enkephalin-gamma-endorphin (ORG 5878). Alcohol Alcohol 1992, 27:373-379.
185. Chen T.J.H., Blum K., Mathews D., et al. Preliminary association of both the Taq1 A1 allele of the dopamine D2 receptor gene and the Dopamine Transporter (DAT1) 480bp allele with pathological aggression in adolescents. Med Hypotheses 2005, 65(4):703-707.
186. Chen C.K., Chen S.L., Mill J., et al. The dopamine transporter gene is associated with attention deficit hyperactivity disorder in a Taiwanese sample. Mol Psychiatry 2003, 8(4):393-396.
187. Comings D.E., Rosenthal R.J., Lesieur H.R., et al. A study of the dopamine D2 receptor gene in pathological gambling. Pharmacogenet 1996, 6(3):223-234.
188. Uhl G., Blum K., Noble E., Smith S. Substance abuse vulnerability and D2 receptor genes. Trends Neurosci 1993, 16(3):83-88.
189. Volkow N.D., Chang L., Wang G.J., et al. Low level of brain dopamine D2 receptors in methamphetamine abusers: Association with metabolism in the orbitofrontal cortex. Am J Psychiatry 2001, 158:377-382.
190. Volkow N.D., Fowler J.S. Addiction, a disease of compulsion and drive: involvement of the orbitofrontal cortex. Cereb Cortex 2000, 10:318-325.
191. Volkow N.D., Fowler J.S., Wang G.J. Role of dopamine in drug reinforcement and addiction in humans: results from imaging studies. Behav Pharmacol 2002, 13:355-366.
192. Volkow N.D., Fowler J.S., Wang G.J. The addicted human brain: insights from imaging studies. J Clin Invest 2003, 111:1444-1451.
193. Thut G., Schultz W., Roelcke U., Nienhusmeier M., Missimer J., Maguire R.P., et al. Activation of the human brain by monetary reward. Neuroreport 1997, 8:1225-1228.
194. Yoshida A., Hsu L., Yasumami M. Genetics of human alcohol-metabolizing enzymes. Prog Nucleic Acid Res Mol Biol 1991, 40:255-287.
195. Crabb D.W., Edenberg H.J., Bosron W.F., Li T.K. Genotypes for aldehyde dehydrogenase deficiency and alcohol sensitivity: the inactive ALDH2*2 is dominant. J Clin Invest 1989, 83:314-316.
196. Yamamoto K., Ueno Y., Mizoi Y., Tatsuno Y. Genetic polymorphism of alcohol and aldehyde dehydrogenase and the effects on alcohol metabolism. Jpn J Alcohol Drug Depend 1993, 28:13-25.
197. Higuchi S., Matsushita T., Imazeki H., Kinoshta T., Tikagi S., Kono H. Aldehyde dehdrogenase genotypes in Japanese alcoholics. Lancet 1994, 343:741-742.
198. Matsushita S., Muramatsu T., Murayama M., Nakane J., Higuchi S. Alcoholism. ALDH2*2 allele and the A1 allele of the dopamine D2 receptor gene: an association study. Psychiatry Res 2001, 104:19-26.
199. Huang S.-Y., Lin W.W., Ko H.-C., et al. Possible interaction of alcohol dehydrogenase and aldehyde dehydrogenase genes with the dopamine D2 receptor gene in anxiety-depressive alcohol dependence. Alcohol Clin Exp Res 2004, 374-384.
200. Lamensdorf I., Eisenhofer G., Harvey-White J., Nechustan A., Kirk K., Kopin I.J. 3,4-Dihydroxyphenylacetaldehyde potentiates the toxic effects of metabolic stress in PC12 cells. Brain Res 2000, 868:191-201.
201. Comings DE, Blum K. Reward Deficiency Syndrome: Genetic Aspects of Behavioral Disorders and Validation. International Meeting On Implications Of Comorbidity For Etiology and Treatment Of Neuropsychiatric Disorders. October 19-23, 2005. Mazagon (Huelva) Spain.
202. Hökfelt T., Elde R., Johansson O., Terenius L., Stein L. The distribution of enkephalin-immunoreactive cell bodies in the rat central nervous system. Neurosci Lett 1977, 5:25-31.
203. De Wied D., Sigling H.O. Neuropeptides involved in the pathophysiology of schizophrenia and major depression. Neurotox Res 2002, 4:453-468.
204. Raevskiǐ K.S., Shemanov AIu V.S., Kudrin Des-1-tyrosine-gamma-endorphin: an assessment of its neuroleptic properties and effect on dopamine synthesis. Farmakol Toksikol 1982, 45:5-8.
205. Schoemaker H., Davis T.P., Pedigo N.W., Chen A., Berens E.S., Ragan P., et al. Identification of beta-endorphin-6(16-17) as the principal metabolite of des-tyrosin-gamma-endorphin (DTgammaE) in vitro and assessment of its activity in neurotransmitter receptor binding assays. Eur J Pharmacol 1982, 81:459-468.
206. Gispen W.H., Ormond D., ten Haaf J., De Wied D. Modulation of ACTH-induced grooming by [Des-Tyr1]-gamma-endorphin and haloperidol. Eur J Pharmacol 1980, 63:203-207.
207. Seeman P. Are dopamine D2 receptors out of control in psychosis?. Prog Neuropsychopharmacol Biol Psychiatry 2013, 46C:146-152.
208. Blum K., Chen T.J., Downs B.W., Bowirrat A., et al. Neurogenetics of dopaminergic receptor supersensitivity in activation of brain reward circuitry and relapse: proposing "deprivation-amplification relapse therapy" (DART). Postgrad Med 2009, 121(6):176-196.
209. Xiao L., Shen T., Peng D.H., Shu C., Jiang K.D., Wang G.H. Functional-141C Ins/Del polymorphism in the dopamine D2 receptor genepromoter and schizophrenia in a Chinese Han population. J Int Med Res 2013, 41:1171-1178.
210. Borroto-Escuela D.O., Ravani A., Tarakanov A.O., et al. Dopamine D2 receptor signaling dynamics of dopamine D2-neurotensin 1 receptor heteromers. Biochem Biophys Res Commun 2013, 435:140-146.
211. Pinacho R., Villalmanzo N., Roca M., et al. Analysis of Sp transcription factors in the postmortem brain of chronic schizophrenia: a pilot study of relationship to negative symptoms. J Psychiatr Res 2013, 47(7):926-934.
212. Glass M.J., Robinson D.C., Waters E., Pickel V.M. Deletion of the NMDA-NR1 receptor subunit gene in the mouse nucleus accumbens attenuates apomorphine-induced dopamine D1 receptor trafficking and acoustic startle behavior. Synapse 2013, 67:265-279.
213. Wang Y., Sasaoka T., Dang M.T. A molecular genetic approach to uncovering the differential functions of dopamine D2 receptor isoforms. Methods Mol Biol 2013, 964:181-200.
214. Novak G., Fan T., O'Dowd B.F., George S.R. Striatal development involves a switch in gene expression networks, followed by a myelination event: implications for neuropsychiatric disease. Synapse 2013, 67:179-188.
215. Giegling I., Balzarro B., Porcelli S., et al. Influence of ANKK1 and DRD2 polymorphisms in response to haloperidol. Eur Arch Psychiatry Clin Neurosci 2013, 263:65-74.
216. Sáiz P.A., García-Portilla M.P., Arango C., et al. Genetic polymorphisms in the dopamine-2 receptor (DRD2), dopamine-3 receptor (DRD3), and dopamine transporter (SLC6A3) genes in schizophrenia: Data from an association study. Prog Neuropsychopharmacol Biol Psychiatry 2010, 34(1):26-31.
217. Urigüen L., García-Fuster M.J., Callado L.F., et al. Immunodensity and mRNA expression of A2A adenosine, D2 dopamine, and CB1 cannabinoid receptors in postmortem frontal cortex of subjects with schizophrenia: effect of antipsychotic treatment. Psychopharmacology (Berl) 2009, 206:313-324.
218. Ponce G., Pérez-González R., Aragüés M., et al. The ANKK1 kinase gene and psychiatric disorders. Neurotox Res 2009, 16:50-59.
219. Lafuente A., Bernardo M., Mas S., et al. Polymorphism of dopamine D2 receptor (TaqIA, TaqIB, and-141C Ins/Del) and dopamine degradation enzyme (COMT G158A, A-278G) genes and extrapyramidal symptoms in patients withschizophrenia and bipolar disorders. Psychiatry Res 2008, 161:131-141.
220. Santana N., Mengod G., Artigas F. Quantitative analysis of the expression of dopamine D1 and D2 receptors in pyramidal and GABAergic neurons of the rat prefrontal cortex. Cereb Cortex 2009, 19:849-860.
221. Moriguchi S., Bies R.R., Remington G., et al. Estimated dopamine D2 receptor occupancy and remission in schizophrenia: analysis of the CATIE data. J Clin Psychopharmacol 2013, 33(5):682-685. 10.1097/JCP.0b013e3182979a0a.
222. Hoenicka J., Aragüés M., Rodríguez-Jiménez R., et al. Psychosis and Addictions Research Group (PARG). C957T DRD2 polymorphism is associated with schizophrenia in Spanish patients. Acta Psychiatr Scand 2006, 114:435-438.
223. Virgos C., Martorell L., Valero J., et al. Association study of schizophrenia with polymorphisms at six candidate genes. Schizophr Res 2001, 49:65-71.
224. Sweatt J.D. The emerging field of neuroepigenetics. Neuron 2013, 80:624-632.